December 17, 2014 4:46 PM ET


Company Overview of Zafgen, Inc.

Company Overview

Zafgen, Inc., a biopharmaceutical company, focuses on the provision of therapeutics for patients suffering from obesity and obesity-related disorders. Its lead product candidate includes Beloranib, an injection that is in Phase II clinical trials for the treatment of various indications comprising obesity and hyperphagia in Prader-Willi Syndrome patients, craniopharyngioma-associated obesity, and severe obesity in the general population. The company is also developing ZGN-839, a methionine aminopeptidase 2 inhibitor, which is in preclinical trials reduces the severity of nonalcoholic steatohepatitis and plasma glucose. Zafgen, Inc. was founded in 2005 and is headquartered in Cambridge, Massa...

One Broadway

8th Floor

Cambridge, MA 02142

United States

Founded in 2005

18 Employees



Key Executives for Zafgen, Inc.

Chief Executive Officer and Director
Age: 54
Total Annual Compensation: $520.0K
Chief Financial Officer and Principal Accounting Officer
Age: 51
Total Annual Compensation: $297.9K
Chief Medical Officer
Age: 43
Total Annual Compensation: $407.0K
Compensation as of Fiscal Year 2013.

Zafgen, Inc. Key Developments

Zafgen Announces Initiation of Phase 2b Trial of Beloranib in Severe Obesity

Zafgen, Inc. announced that the Company has initiated a Phase 2b clinical trial with its lead product candidate, beloranib, in the treatment of patients with both severe obesity and type 2 diabetes. The trial is a randomized, double-blind, placebo-controlled design in severely obese adults with a BMI between 30 and 60 kg/m2, and type 2 diabetes. The trial will aim to demonstrate weight loss over a 6 – 12 month period, along with improvements in glycemic control, and is expected to enroll 150 patients at approximately 15 sites across Australia. Patients enrolled will be randomized to receive placebo, 1.2 mg or 1.8 mg of beloranib, twice weekly subcutaneous injections during the randomized treatment period of 12 months. The primary efficacy endpoint is change in total body weight from baseline to the end of randomized treatment. Key secondary endpoints include changes in glycemic control, lipid parameters and inflammatory markers. Additional assessments include sense of hunger and quality of life impact for patients.

Zafgen, Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014

Zafgen, Inc. reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company reported a net loss attributable to common stockholders of $14.7 million, or $0.65 per basic and diluted share compared to a $3.5 million or $4.88 per basic and diluted share, for the three months ended September 30, 2013. Loss from operations was $14,361,000 compared with $3,524,000 for the same period a year ago. For the nine months, the company reported loss from operations of $24.868 million against $10.019 million a year ago. Net loss attributable to common stockholders was $25.639 million or $2.97 per basic and diluted share against $10.341 million or $14.19 per basic and diluted share a year ago.

Zafgen, Inc., Q3 2014 Earnings Call, Nov 11, 2014

Zafgen, Inc., Q3 2014 Earnings Call, Nov 11, 2014

Similar Private Companies By Industry

Company Name Region
SKS Ocular, LLC United States
Triad Isotopes, Inc. United States
Gamma Biologicals, Inc. United States
Pacific Biotech, Inc. United States
Vicept Therapeutics Incorporated United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Zafgen, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at